Table 5.

HR, with 95% CI and p values, for the effect of RA, AS, PSA, SLE and SSc on all-cause mortality of patients <50 years and ≥50 years of age for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

Systemic rheumatic disease	Age (years)	0–36 months of follow-up			>36 months of follow-up
		HR (main effect)			HR (main effect)
			95% CI	P value		95% CI	P value
RA	<50	0.43	0.28 to 0.69	<0.001	1.36**	0.72 to 2.59	0.345
	≥50	0.63	0.60 to 0.67	<0.001	1.12*	1.04 to 1.21	0.002
AS	<50	0.57	0.33 to 0.96	0.037	0.57	0.33 to 0.96	0.037
	≥50	0.65	0.52 to 0.83	<0.001	1.04**	0.77 to 1.41	0.806
PsA	<50	0.52	0.28 to 0.95	0.036	0.52	0.28 to 0.95	0.036
	≥50	0.69	0.60 to 0.79	<0.001	1.08*	0.89 to 1.31	0.418
SLE	<50	2.74	1.92 to 3.92	<0.001	2.74	1.92 to 3.92	<0.001
	≥50	1.47	1.30 to 1.66	<0.001	1.89*	1.59 to 2.25	<0.001
SSc	<50	5.18	2.71 to 9.89	<0.001	5.18	2.71 to 9.89	<0.001
	≥50	2.2	1.82 to 2.66	<0.001	4.01**	3.00 to 5.37	<0.001

P value for interaction *<0.001; **<0.05.

AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.